ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1590

Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc

Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Emily Langballe2, Hilde Jenssen Bjørkekjær3, Henriette Didriksen1, Phuong Phuong Diep4, Anna Helena Andersson1, Ragnar Gunnarsson1, Michael T Durheim1, Torhild Garen1, Øyvind Midtvedt5, Trond Mogens Aaløkken6, Øyvind Molberg7 and Oliver Distler8, 1Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, 4Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, 5Oslo University Hospital, Oslo, Oslo, Norway, 6Medicine, Oslo, Norway, Oslo, Norway, 7Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, interstitial lung disease, prognostic factors, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). While impaired lung function with forced vital capacity (FVC) < 70% and extensive lung fibrosis by predict excess mortality in SSc, the risk conferred by less advanced ILD is not fully clear. This question has major clinical implications. If even mild SSc-ILD is associated with overall mortality and, more specifically, respiratory causes of death, there is a potential need for aggressive and better-defined management approaches early in the disease. Here, we assessed respiratory causes of deaths in SSc-ILD patients and evaluate the impact of general, SSc-, and lung characteristics on respiratory-caused mortality in patients with preserved lung function.

Methods: The study cohort included SSc-ILD patients (N=323) from the Norwegian SSc cohort who had ILD diagnosed by HRCT, and had prospective clinical data available. The Norwegian national population registry provided vital status for all patients. We obtained causes of death from death certificates and by chart review and segregated them into respiratory and non-respiratory causes. General, SSc-specific, and lung characteristics were determined for associations with respiratory causes of death.The severity of ILD was defined as mild or severe ILD based on lung function (FVC% predicted ≥/< 70%), the extent of ILD on HRCT < /≥10%, and the absence or presence of respiratory symptoms (WHO functional class ≤/ >2). We used logistic regression to assess the impact of characteristics on respiratory-caused mortality in mild ILD based on preserved lung function.

Results: Out of 323 SSc-ILD patients, 132 (41%) were deceased. Causes of death were available for 99 (76%) patients (Table 1A). Of these, 24 (24%) died of respiratory causes, with 67% dying of respiratory tract infections and 33% of respiratory failure (Figure 1A). Among the 24 patients who died of respiratory causes, 50% had FVC ≥70%, 57% had ≤10% extent of ILD on HRCT, and 44% had reported absence of respiratory symptoms mean 1.1 year prior to death (Table 1A). Next, we aimed to identify clinical characteristics of patients dying of respiratory caused mortality with preserved lung function. We compared the characteristics of the 12 SSc-ILD patients with preserved lung function (defined as FVC ≥70%) who died of respiratory causes to 104 surviving peers (Table 1B). We found that older age, male sex, progressive ILD defined as FVC decline, the presence of respiratory symptoms, reduced six-minute walking distance (6MWD), and the development of pulmonary hypertension (PH) were associated with mortality despite preserved lung function (Table 1B). The main cause of respiratory deaths in these patients was respiratory tract infections (75%) (Figure 1B). No specific SSc manifestations were identified to be associated with respiratory-caused mortality (Figure 2).

Conclusion: A significant proportion of SSc-ILD patients who died of respiratory causes had preserved lung function and did not progress to more severe, end-stage lung disease. Our results highlight the importance of preventing the onset of ILD, as well as halting its progression, even in cases of mild ILD, to improve ILD-associated survival in SSc patients.

Supporting image 1

Figure 1A: Causes of respiratory deaths in 24 SSc-ILD patients, Figure 1B: Causes of respiratory deaths in 12 SSc-ILD patients with FVC>70% at time of death

Supporting image 2

Table 1: Patient characteristics of deceased SSc-ILD patients segregated by respiratory or non-respiratory cause of death

Supporting image 3

Table 2: Patient characteristics of deceased SSc-ILD patients dying of respiratory cause with FVC>70% at time point of death compared to alive SSc-ILD patients with FVC>70%


Disclosures: A. Hoffmann-Vold: Arxx Therapeutics, 2, Boehringer Ingelheim, 2, 5, 6, 12, Support for travel, Genentech, 2, Janssen, 2, 5, 6, Medscape, 2, 6, 12, Support for travel, Merck/MSD, 2, Novartis, 6, Pliant Therapeutics, 2, Roche, 2, 6, 12, Support for travel, Werfen, 2; H. Fretheim: Bo, 6; E. Langballe: None; H. Jenssen Bjørkekjær: None; H. Didriksen: None; P. Diep: None; A. Andersson: None; R. Gunnarsson: None; M. Durheim: None; T. Garen: None; Ø. Midtvedt: None; T. Aaløkken: None; Ø. Molberg: None; O. Distler: 4P-Pharma, 2, “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143), 10, AbbVie, 2, Acceleron, 2, Alcimed, 2, Altavant Sciences, 2, Amgen, 2, AnaMar, 2, Arxx, 2, AstraZeneca, 2, Bayer, 2, 6, Blade Therapeutics, 2, Boehringer Ingelheim, 2, 5, 6, Citrus AG, 12, Co-founder, Corbus Pharmaceuticals, 2, CSL Behring, 2, EMD Serono, 2, ERS/EULAR Guidelines, 12, Co-Chair, EUSTAR, 12, President, FOREUM Foundation, 12, Chair of Executive Committee, Galapagos, 2, Glenmark, 2, Gossamer, 2, Hartmann Müller Foundation, 12, Member Board of Trustees, Horizon, 2, Janssen, 2, 6, Kymera, 2, 5, Lupin, 2, Medscape, 2, 6, Merck/MSD, 2, Miltenyi Biotec, 2, Mitsubishi Tanabe, 2, 5, Nkarta Inc., 2, Novartis, 2, Orion, 2, Prometheus Biosciences, 2, Redxpharma, 2, Roivant, 2, Swiss Academy of Medical Sciences, 12, Senat Member, Swiss Clinical Quality Management in Rheumatic Diseases, 12, Member Board of Trustees, Topadur, 2, UCB, 2.

To cite this abstract in AMA style:

Hoffmann-Vold A, Fretheim H, Langballe E, Jenssen Bjørkekjær H, Didriksen H, Diep P, Andersson A, Gunnarsson R, Durheim M, Garen T, Midtvedt Ø, Aaløkken T, Molberg Ø, Distler O. Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/milder-ild-with-preserved-lung-function-significantly-contributes-to-respiratory-caused-mortality-in-ssc/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/milder-ild-with-preserved-lung-function-significantly-contributes-to-respiratory-caused-mortality-in-ssc/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology